Aspen Neuroscience: McDevitt reports 485,751 trust shares

One option is fully vested and exercisable; unvested shares under the other vest monthly through November 20, 2031, subject to continuous service.

Accepted by SEC EDGAR 10/29/2026 - 08:04 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Aspen Neuroscience, Inc. director and officer Damien McDevitt reported 485,751 shares held by the Marnell-McDevitt Family Trust, where he and Pamela Marnell-McDevitt are co-trustees, plus 25,299 shares each in trusts for Finn McDevitt, Aran McDevitt and Conor McDevitt, as of October 29, 2026. Of the family-trust shares, 93,607 are subject to performance-based vesting and repurchase if conditions are unmet or his service ends. His direct options cover 196,820 shares at $8.70 and 387,063 shares at $5.74; the latter’s unvested shares as of July 20, 2026 vest monthly through November 20, 2031, subject to continuous service.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider McDevitt Damien

Role See Remarks

Type	Security	Shares	Price	Value
Holding	Stock Option (Right to Buy) F5	--	--	--
Holding	Stock Option (Right to Buy) F6	--	--	--
Holding	Common Stock F1	--	--	--
Holding	Common Stock F2	--	--	--
Holding	Common Stock F3	--	--	--
Holding	Common Stock F4	--	--	--

Holdings: Stock Option (Right to Buy) — 583,883 contracts (Direct); Common Stock — 485,751 shares (Indirect, See Footnote 1.); Common Stock — 25,299 shares (Indirect, See Footnote 2.); Common Stock — 25,299 shares (Indirect, See Footnote 3.); Common Stock — 25,299 shares (Indirect, See Footnote 4.)

Footnotes (6)

1. F1. Shares of Common Stock held by Damien McDevitt and Pamela Marnell-McDevitt, Co-trustees of the Marnell-McDevitt Family Trust dated May 2, 2019, of which 93,607 shares remain subject to performance-based vesting conditions and to repurchase by the Issuer if such conditions are not met or upon termination of the Reporting Person's service.
2. F2. Shares of Common Stock held by Finn McDevitt, Trustee of the Finn McDevitt 2025 Irrevocable Trust.
3. F3. Shares of Common Stock held by Aran McDevitt, Trustee of the Aran McDevitt 2025 Irrevocable Trust.
4. F4. Shares of Common Stock held by Conor McDevitt, Trustee of the Conor McDevitt 2025 Irrevocable Trust.
5. F5. The option was granted on December 16, 2024. The option is fully vested and exercisable.
6. F6. The option was granted on November 26, 2025. The shares subject to the option were previously eligible to vest in 48 equal monthly installments beginning on December 20, 2025. In August 2026, the vesting schedule was amended such that the unvested shares subject to the option as of July 20, 2026, shall vest in equal monthly installments through November 20, 2031, subject to the Reporting Person's continuous service through each vesting date.

Key Figures

Marnell-McDevitt Family Trust common shares: 485,751 shares Common shares in each of three other trusts: 25,299 shares Shares subject to performance-based vesting: 93,607 shares +4 more

7 metrics

Marnell-McDevitt Family Trust common shares 485,751 shares As of October 29, 2026

Common shares in each of three other trusts 25,299 shares Each trust; as of October 29, 2026

Shares subject to performance-based vesting 93,607 shares Marnell-McDevitt Family Trust

First stock option underlying shares 196,820 shares Direct option; fully vested and exercisable

First option exercise price $8.70 per share Direct stock option

Second stock option underlying shares 387,063 shares Direct option; vesting subject to continuous service

Second option exercise price $5.74 per share Direct stock option

Key Terms

performance-based vesting conditions, fully vested and exercisable, continuous service

3 terms

performance-based vesting conditions financial

"shares remain subject to performance-based vesting conditions"

fully vested and exercisable financial

"The option is fully vested and exercisable"

continuous service financial

"subject to the Reporting Person's continuous service through each vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What vesting terms apply to Damien McDevitt’s ASPE stock options?

The option covering 196,820 shares is fully vested and exercisable; the 387,063-share option has unvested shares as of July 20, 2026 scheduled to vest in equal monthly installments through November 20, 2031, subject to continuous service through each vesting date. The first option was granted December 16, 2024 and expires December 15, 2034; the second was granted November 26, 2025 and expires November 25, 2035. Its vesting schedule was amended in August 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

McDevitt Damien

(Last) (First) (Middle)

10835 ROAD TO THE CURE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/29/2026

3. Issuer Name and Ticker or Trading Symbol
Aspen Neuroscience, Inc. [ ASPE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	485,751	I	See Footnote 1.(1)
Common Stock	25,299	I	See Footnote 2.(2)
Common Stock	25,299	I	See Footnote 3.(3)
Common Stock	25,299	I	See Footnote 4.(4)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(5)	12/15/2034	Common Stock	196,820	$8.7	D
Stock Option (Right to Buy)	(6)	11/25/2035	Common Stock	387,063	$5.74	D

Explanation of Responses:

1. Shares of Common Stock held by Damien McDevitt and Pamela Marnell-McDevitt, Co-trustees of the Marnell-McDevitt Family Trust dated May 2, 2019, of which 93,607 shares remain subject to performance-based vesting conditions and to repurchase by the Issuer if such conditions are not met or upon termination of the Reporting Person's service.

2. Shares of Common Stock held by Finn McDevitt, Trustee of the Finn McDevitt 2025 Irrevocable Trust.

3. Shares of Common Stock held by Aran McDevitt, Trustee of the Aran McDevitt 2025 Irrevocable Trust.

4. Shares of Common Stock held by Conor McDevitt, Trustee of the Conor McDevitt 2025 Irrevocable Trust.

5. The option was granted on December 16, 2024. The option is fully vested and exercisable.

6. The option was granted on November 26, 2025. The shares subject to the option were previously eligible to vest in 48 equal monthly installments beginning on December 20, 2025. In August 2026, the vesting schedule was amended such that the unvested shares subject to the option as of July 20, 2026, shall vest in equal monthly installments through November 20, 2031, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

Exhibit 24 - Power of Attorney President and Chief Executive Officer

	By: /s/ Jeffrey L. Boerneke, as Attorney-in-Fact	10/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)